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Now that he’s run his own laboratory for 
19 years, Jan van Deursen looks back at his 
doctoral student days with wry amusement. 
His advisor, Bé Wieringa at the University 
of Nijmegen in the Netherlands, put him 
on a project to make one of the fi rst genetic 
knockout mice. “What was he thinking?” 
van Deursen now wonders.
The mouse, lacking the muscle creatine 
kinase gene, had totally normal muscles but 
could not sprint to save its life (1). That pio-
neering work allowed van Deursen to essen-
tially skip postdocing and establish his own 
group at St. Jude Children’s Research Hos-
pital in Memphis, Tennessee, in 1996. In 
1999, he moved to the Mayo Clinic in Roch-
ester, Minnesota, where he used his experi-
ence with genetically engineered mice to 
probe how aneuploidy relates to cancer 
(2, 3) and investigate the cell biology of 
senescence (4, 5). Another powerful genetic 
manipulation—using apoptosis through 
targeted activation of caspase (ATTAC) to 
remove senescent cells—allowed his lab-
oratory to make their biggest splash yet 
by delaying aging in a prog-
eroid mouse model (6).
Now, the cancer biologist 
is chair of biochemistry and 
molecular biology at Mayo. 
He recently chatted with 
JCB about his obsession 
with decades-old hypotheses 
and why he’s not seeking 
the fountain of youth.
COUNTING 
CHROMOSOMES
Did mastering transgenic technology 
early on launch your career?
From the beginning, I was fascinated by 
the potential of the technology. When I 
was done with my PhD, there were very 
few people in the world who had the skills 
to go through the whole procedure. I got 
many job offers simply because a lot of 
institutes wanted to set up a facility.
My PhD advisor said, “That’s fi ne for 
you to help others knock out their most 
interesting genes, but you also need to 
develop your own research program.” 
That was really good advice at the time.
When I started my own program, I be-
came very interested in Nup98, a compo-
nent of the nucleocytoplasmic transport 
machinery that was implicated in cancer. 
I wanted to figure out what the normal 
roles of Nup98 and its binding partner 
Rae1 were. Eventually, we showed that 
the Rae1–Nup98 complex is a mitotic 
regulator that prevents aneuploidy.
Which comes ﬁ rst, aneuploidy or cancer?
That question really drew me to this fi eld. 
Aneuploidy was thought to drive cancer—
that hypothesis was 100 years old at the 
time—but there was really no good in 
vivo evidence.
When we independently knocked out 
Rae1 or Bub3, a structurally related protein, 
we found that both had mitotic phenotypes—
cells cannot accurately segregate their chro-
mosomes. But surprisingly few cancers de-
veloped in these mice. The thinking at that 
time was that if a cell becomes aneuploid, 
it’s really on the highway to 
cancer. That didn’t seem to 
be the case.
Was that disappointing?
My sense is that a lot of 
people in the fi eld were dis-
appointed and moved on to 
something else. We stuck 
with it because I wanted 
to better understand how 
aneuploidy might contrib-
ute to cancer.
We challenged these animals with car-
cinogens or hits to critical tumor suppressor 
genes, and we found that mutations in 
mitotic checkpoint proteins could accel-
erate tumorigenesis in some cases.
Today, I think there is a lot of evidence 
that cancer can be an outcome of aneu-
ploidy, but it’s not an obligatory outcome. 
There are maybe 500–600 genes in humans, 
that, when you alter them, cause chromo-
some number instability. Now we are fi nally 
starting to make progress on which of these 
genes, when mutated, actually predispose 
you to tumorigenesis, and why.
AN ODDBALL MODEL
Much of the work in your lab relies on 
mice with various levels of gene 
expression, using heterozygous or 
hypomorphic strains. Why this approach?
Hypomorphic mutations initially arose 
from aberrant gene-targeting events that 
reduced normal messenger RNA by 90% 
or so. That was a way to get protein at a 
much lower level than you would have 
from a heterozygote.
When I had these embryonic lethal phe-
notypes for the checkpoint proteins, using 
hypomorphic mice became very valuable. 
You could get much lower than just the 
50% of normal protein of a heterozygote.
Hypomorphs were basically artifacts 
from my PhD, but it was a great infl uence 
on how my research developed. And it led to 
the most interesting animal model that I’ve 
ever made: the BubR1 hypomorphic mouse.
What made it so interesting?
We were trying to create a cancer model for 
aneuploidy. But instead of developing cancer, 
those mice aged at a highly accelerated rate.
It took us a couple of years to fi gure out 
the phenotype, because the model was re-
ally odd. After four to fi ve months, the mice 
started to look like they were very, very sick. 
They looked like they would keel over at 
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van Deursen’s career visits both sides of the cancer–senescence coin.
Jan van Deursen: From knockout pioneer to antiaging innovator
“There is a lot 
of evidence 
that cancer can 
be an outcome 
of aneuploidy, 
but it’s not 
an obligatory 
outcome.”
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any moment, but they could look like that 
for several months. Finally, I saw a picture 
of a trichothiodystrophy (TTD) mutant 
mouse, which is predisposed to DNA dam-
age. It started to click that we had a model of 
a progeroid syndrome.
Two months after our paper came out in 
Nature Genetics, another paper showed there 
are people with mutations in BubR1 who 
have a similar accelerated aging syndrome.
Does BubR1 play a role in normal aging?
In older, normal mice, the levels of BubR1 
drop to the same level as in our hypomorphic 
mice with this progeroid syndrome. But the 
key fi nding was that the tissues subjected to 
this accelerated aging accumulated a lot of 
cells that were senescent. We started to think 
that maybe either the formation or presence 
of these cells has something to do with the 
age-related decline in tissue function.
Maybe I’m not that original, because 
everyone thought we already knew this. 
When Leonard Hayfl ick and Paul Moor-
head coined the term “senescence” in 1961, 
they proposed that, when cells run out of 
proliferative potential, it should affect tis-
sue renewal and therefore tissue function.
But then there’s 50 years where nobody 
was really able to provide in vivo evidence 
for a connection between the accumulation 
of senescent cells and the development of 
age-related decline or pathologies. My lab 
was basically handed that trophy.
How did you show that connection?
We had a very simple approach. If we could 
prevent cells from going into senescence, 
maybe we could delay the onset of age-
related pathologies such as muscle wasting, 
fat dysfunction, and cataracts.
So we looked at the pathways that were 
thought to drive cells into senescence: the 
p16 and p53 pathways. We knocked out the 
p16 pathway in our BubR1 hypomorphic 
mice, and you couldn’t fi nd any senescent 
cells. And the mice looked healthier—they 
didn’t age as fast.
To confirm this, we tried to remove 
senescent cells after they had formed to 
see if we could get the same antiaging 
effect. We designed a transgenic mouse, 
in which we could use a drug to induce 
p16-positive cells to undergo apoptosis. 
When we crossed this into the BubR1 hypo-
morphic background, we removed se-
nescent cells after they ac-
cumulated, and, again, the 
mice didn’t age as fast.
SLOWING DOWN AGING
Why does removing 
senescent cells have such 
a dramatic effect?
Senescent cells might only 
represent 1–5% of the cells in 
a tissue. But they are so aggressive—their 
secretome consists of proteases, growth 
factors, and infl ammatory cytokines that 
have a very profound effect on the neigh-
boring cells and the tissue as a whole.
That’s actually perfect if you think about 
it as a therapeutic approach: get rid of a few 
cells and make a big impact on the organ, 
but still keep the tissue structure and cellu-
larity largely intact.
Were there skeptics about this 
“fountain-of-youth” mechanism?
Many in the fi eld don’t believe that proge-
roid models refl ect natural aging. So we’ve 
started investigating what happens when you 
get rid of senescent cells in normal mice.
Interestingly, the 2011 Nature paper 
where we forced these cells into apoptosis 
mimicked what you could maybe achieve 
with a drug that targets senescent cells.
Was there a media frenzy?
It was a little bit uncontrolled. The New York 
Times wanted to do an interview, and then 
called back the next day to say they wanted 
to put the story on the front page and they 
needed a picture of the mice. I remember 
spending a couple of hours in the mouse 
room, because it’s not so easy to take side-
by-side pictures of mice. They don’t sit still.
Then it was crazy for a while. I realized 
that researchers have to deal with laypeople 
who have their own expectations or see our 
work from their own perspectives. It made 
me realize that one has to be careful when 
translating laboratory fi ndings about aging 
because people seem to be paying attention.
Will we soon have a pill to slow aging?
If I was a naïve scientist, I would be extreme-
ly optimistic. But since I have attended many 
meetings with people who have expertise 
in developing drugs, this makes me approach 
it more like a marathon, rather 
than a sprint.
I’m 52 and I like to run mar-
athons, but I’ve had to face my 
decline. I have three teenagers 
who remind me daily that I’m 
old! But I’m not the type of per-
son who wants to know, “Can 
I slow down my aging?” 
I think everyone wants to 
have a long and healthy life. But the em-
phasis is on healthy. You hardly ever meet 
people who want to live longer and suffer.
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A 5-month-old BubR1 hypomorphic progeroid 
mouse (left) sits next to its littermate control 
(right). The background shows an example of 
premature sister chromatid separation visual-
ized by spectral karyotyping.
“The New 
York Times…
wanted to 
put the story 
on the 
front page.”
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van Deursen and Mayo colleague Rick Bram 
wait to start the 2013 Boston Marathon.
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